VAMG
CRSP icon

Voisard Asset Management Group’s CRISPR Therapeutics CRSP Stock Holding History

Voisard Asset Management Group’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-200
Closed -$9.4K – 195
2024
Q3 		$9.4K Hold
200
– – ﹤0.01% 305
2024
Q2 		$10.8K Hold
200
– – 0.01% 257
2024
Q1 		$13.6K Hold
200
– – 0.01% 217
2023
Q4 		$12.5K Buy
+200
New +$11.1K 0.01% 228

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Voisard Asset Management Group's CRSP Position: Q4 2024 in Review

Voisard Asset Management Group sold out of CRISPR Therapeutics (CRSP) in Q4 2024, closing a stake of 200 shares — an estimated $9.4K sold.

Voisard Asset Management Group first reported a position in CRSP in Q4 2023 and held it in 4 quarters. The position peaked at $13.6K in Q1 2024. 404 funds tracked by Wall St. Rank hold CRSP as of Q4 2024.

  • Voisard Asset Management Group reported no remaining CRISPR Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Voisard Asset Management Group sold 200 CRISPR Therapeutics shares in Q4 2024, an estimated $9.4K.
  • Voisard Asset Management Group first reported a position in CRISPR Therapeutics in Q4 2023 and held it in 4 quarters.
  • Voisard Asset Management Group's CRISPR Therapeutics position peaked at $13.6K in Q1 2024.
  • 404 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q4 2024.

Based on Voisard Asset Management Group's 13F filing for Q4 2024, filed 7 Feb 2025.